Perspective Therapeutics, Inc. ("Perspective” or the "Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced ...

Consistent with known effects of GLP-1/GIP therapy ... There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which ...

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study.

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained ... and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these ...

Inositol 1,4,5-trisphosphate receptors (ITP3Rs a.k.a. IP3Rs) are intracellular calcium release channels that play a critical role in calcium signaling, influencing cardiac remodeling and fibrosis. In ...

Perspective Therapeutics, Inc.’s CATX share price has dipped by 5.02%, which has investors questioning if this is right time ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific ...

There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, ...